Ignite Creation Date:
2024-05-06 @ 2:23 PM
Last Modification Date:
2024-10-26 @ 1:30 PM
Study NCT ID:
NCT04307511
Status:
RECRUITING
Last Update Posted:
2024-04-22
First Post:
2020-03-08
Brief Title:
A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients
Sponsor:
Shanghai Tong Ren Hospital
Organization:
Shanghai Tong Ren Hospital
Study Overview
Official Title:
A Randomized Controlled sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TIGER-diabetes
Brief Summary:
In this study the investigates try to confirm the hypothesis that low dose ticagrelor60mg had similar anti-platelets function compared with the standard dose ticagrelor in acute coronary syndrome patients with diabetes Totally 40 ACS patients with diabetes will be divided into 2 groups randomly after PCI for one month Group 1 will be treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group Group2 will be treated with ticagrelor 60mg plus aspirin 100 mg for 11 months after one month standard DAPT treatment The platelets function will be tested in VASP and TEG methods at 1 and 2 months after PCI as the primary endpointsThe clinical events will be observed 12 months after PCI
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None